Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).

MR Middleton; O Hamid; AN Shoushtari; FE Meier; TM Bauer; AKS Salama; JM Kirkwood; PA Ascierto; P Lorigan; C Mauch; MM Orloff; TRJ Evans; SE Abdullah; Y Yuan; J Mitchell; JC Hassel

Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).

MR Middleton, O Hamid, AN Shoushtari, FE Meier, TM Bauer, AKS Salama, JM Kirkwood, PA Ascierto, P Lorigan, C Mauch, MM Orloff, TRJ Evans, SE Abdullah, Y Yuan, J Mitchell, JC Hassel

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
Issue number	16
Publication status	Published - 1 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Middleton, MR., Hamid, O., Shoushtari, AN., Meier, FE., Bauer, TM., Salama, AKS., Kirkwood, JM., Ascierto, PA., Lorigan, P., Mauch, C., Orloff, MM., Evans, TRJ., Abdullah, SE., Yuan, Y., Mitchell, J., & Hassel, JC. (2022). Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). Journal of Clinical Oncology, 40(16).

@article{921967fbb2cf40d9a6c470acdcf591e7,

title = "Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).",

author = "MR Middleton and O Hamid and AN Shoushtari and FE Meier and TM Bauer and AKS Salama and JM Kirkwood and PA Ascierto and P Lorigan and C Mauch and MM Orloff and TRJ Evans and SE Abdullah and Y Yuan and J Mitchell and JC Hassel",

year = "2022",

month = jun,

day = "1",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "16",

}

Middleton, MR, Hamid, O, Shoushtari, AN, Meier, FE, Bauer, TM, Salama, AKS, Kirkwood, JM, Ascierto, PA, Lorigan, P, Mauch, C, Orloff, MM, Evans, TRJ, Abdullah, SE, Yuan, Y, Mitchell, J & Hassel, JC 2022, 'Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).', Journal of Clinical Oncology, vol. 40, no. 16.

Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). / Middleton, MR; Hamid, O; Shoushtari, AN et al.
In: Journal of Clinical Oncology, Vol. 40, No. 16, 01.06.2022.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).

AU - Middleton, MR

AU - Hamid, O

AU - Shoushtari, AN

AU - Meier, FE

AU - Bauer, TM

AU - Salama, AKS

AU - Kirkwood, JM

AU - Ascierto, PA

AU - Lorigan, P

AU - Mauch, C

AU - Orloff, MM

AU - Evans, TRJ

AU - Abdullah, SE

AU - Yuan, Y

AU - Mitchell, J

AU - Hassel, JC

PY - 2022/6/1

Y1 - 2022/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000863680300099&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).

UN SDGs

Other files and links

Cite this